Karaganda

Researchers are evaluating the safety and effectiveness of three different doses of MORF-057 in adults with moderately to severely active Crohn's disease (CD). This Phase 2 study is randomized, double-blind, placebo-controlled, and conducted at multiple centers. It aims to compare MORF-057 to placebo to see how well it works in reducing disease activity and symptoms in this patient population. Participants will first go through a 14-week induction period where they receive one of three doses of MORF-057 or a matching placebo, all given orally. After this, all participants will enter a 38-week maintenance phase where they receive open-label MORF-057. Those who complete these 52 weeks of treatment may continue in a 52-week long-term extension to further monitor treatment effects and safety. Throughout the study, participants will have evaluations to assess their response to treatment using endoscopic scoring at Week 14. Researchers will monitor safety, symptom changes, and disease activity over the full treatment and extension periods. Study visits will include assessments, questionnaires, and clinical monitoring to track participants' health and treatment adherence over time.

This research aims to describe the rate of chronic kidney disease (CKD) diagnosis in patients with arterial hypertension (high blood pressure) and markers of CKD in Kazakhstan. The study is a multicenter, non-interventional, prospective observational study that also includes retrospective analysis. It focuses on patients with hypertension and markers such as albuminuria or reduced kidney filtration rate (GFR below 60 ml/min/1.73 m2). Participants are adults diagnosed with hypertension according to clinical guidelines, with specific laboratory markers of CKD measured within the last 12 months and persisting for at least 3 months. The study does not involve any interventions or treatments and observes patients' existing conditions and therapies. It evaluates the proportion of patients with CKD markers among those with hypertension and further assesses demographic and clinical characteristics as well as routine therapies before and after CKD diagnosis. During the study, researchers will collect data on patient medical records, laboratory test results, and diagnoses. The primary outcome is the proportion of patients with CKD markers within 16 months. Secondary outcomes include further evaluation of patients with confirmed CKD diagnoses. The study spans prospective observation and retrospective review, focusing on real-world clinical information without altering patient care.

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.